The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Resistance to enfuvirtide, the first HIV fusion inhibitor
Abstract
Fusion inhibitors are a new class of antiretroviral drugs (ARVs) for the treatment of human immunodeficiency virus infection. Enfuvirtide is the first in this class to reach market approval. Fusion inhibitors block the last step in the three-step viral entry process consisting of attachment, co-receptor binding and fusion, thereby preventing viral capsid entry into the host cell. Enfuvirtide has a unique mechanism of action and high viral target specificity, and in clinical trials has been shown to exhibit both high efficacy and low toxicity. Enfuvirtide is a peptide mimetic of an essential region within viral envelope glycoprotein gp41 that functions by blocking gp41 structural rearrangements at a transitional pre-fusion conformation. Although different clinical isolates show variation in susceptibility to enfuvirtide, primary resistance has not been observed, and thus enfuvirtide-naive isolates remain clinically sensitive. Acquired resistance centres round a 10 amino acid motif between residues 36 and 45 in gp41 that forms part of the binding site of enfuvirtide. The 10 amino acid motif is critical for viral fusion, and enfuvirtide-resistant mutants show poor replicative capacity compared with wild type. Reversion to a wild-type, drug-sensitive state has been reported following enfuvirtide withdrawal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,405
HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor
Feng, Y., Broder, C. C., Kennedy, P. E., & Berger, E. A. (1996) · Science · doi:10.1126/science.272.5263.872 · Cited by 4,172
Identification of a major co-receptor for primary isolates of HIV-1
Deng, H., Liu, R., Ellmeier, W., Choe, S., Unutmaz, D., Burkhart, M., Marzio, P. D., Marmon, S., Sutton, R. E., Hill, C. M., et al. (1996) · Nature · doi:10.1038/381661a0 · Cited by 3,641
HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5
Dragic, T., Litwin, V., Allaway, G. P., Martin, S. R., Huang, Y., Nagashima, K. A., Cayanan, C., Maddon, P. J., Koup, R. A., Moore, J. P., et al. (1996) · Nature · doi:10.1038/381667a0 · Cited by 3,174
Atomic structure of the ectodomain from HIV-1 gp41
Weissenhorn, W., Dessen, A., Harrison, S. C., Skehel, J. J., & Wiley, D. C. (1997) · Nature · doi:10.1038/387426a0 · Cited by 1,622
Wei, X., Decker, J. M., Liu, H., Zhang, Z., Arani, R. B., Kilby, J. M., Saag, M. S., Wu, X., Shaw, G. M., & Kappes, J. C. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1896-1905.2002 · Cited by 1,569
Carr, A., Samaras, K., Thorisdottir, A., Kaufmann, G. R., Chisholm, D. J., & Cooper, D. A. (1999) · The Lancet · doi:10.1016/s0140-6736(98)08468-2 · Cited by 1,495
Adverse effects of antiretroviral therapy
Carr, A., & Cooper, D. A. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02854-3 · Cited by 1,057
Carpenter, C. C. J., Cooper, D. A., Fischl, M. A., Gatell, J. M., Gazzard, B. G., Hammer, S. M., Hirsch, M. S., Jacobsen, D. M., Katzenstein, D. A., Montaner, J. S. G., et al. (2000) · JAMA · doi:10.1001/jama.283.3.381 · Cited by 1,012
Staszewski, S., Morales-Ramirez, J., Tashima, K. T., Rachlis, A., Skiest, D., Stanford, J., Stryker, R., Johnson, P., Labriola, D. F., Farina, D., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912163412501 · Cited by 993
Cited by
Coronaviruses — drug discovery and therapeutic options
Zumla, A., Chan, J. F. W., Azhar, E. I., Hui, D. S. C., & Yuen, K.-Y. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.37 · Cited by 1,707
Synthetic therapeutic peptides: science and market
Vlieghe, P., Lisowski, V., Martinez, J., & Khrestchatisky, M. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2009.10.009 · Cited by 1,476
Discovery and Optimization of a Natural HIV-1 Entry Inhibitor Targeting the gp41 Fusion Peptide
Münch, J., Ständker, L., Adermann, K., Schulz, A., Schindler, M., Chinnadurai, R., Pöhlmann, S., Chaipan, C., Biet, T., Peters, T., et al. (2007) · Cell · doi:10.1016/j.cell.2007.02.042 · Cited by 261
Metadata
- Authors
- Greenberg, M. L.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-07-01
- Volume
- 54
- Issue
- 2
- Pages
- 333-340
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2107672429
- Cited by
- 258
- References
- 71
- FWCI
- 11.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Resistance to enfuvirtide, the first HIV fusion inhibitor. https://app.cochat.ai/papers/10.1093/jac/dkh330
- The paper
- Greenberg, M. L. (2004). Resistance to enfuvirtide, the first HIV fusion inhibitor. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkh330
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.